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Abstract
Background: DNA methylation in the SHOX2 locus was previously used to reliably detect lung cancer in a group
of critical controls, including ‘cytologically negative’ samples with no visible tumor cell content, at a high specificity
based on the analysis of bronchial lavage samples. This study aimed to investigate, if the methylation correlates
with SHOX2 gene expression and/or copy number alterations. An amplification of the SHOX2 gene locus together
with the observed tumor-specific hypermethylation might explain the good performance of this marker in
bronchial lavage samples.
Methods: SHOX2 expression, gene copy number and DNA methylation were determined in lung tumor tissues and
matched morphologically normal adjacent tissues (NAT) from 55 lung cancer patients. Quantitative HeavyMethyl
(HM) real-time PCR was used to detect SHOX2 DNA methylation levels. SHOX2 expression was assayed with
quantitative real-time PCR, and copy numbers alterations were measured with conventional real-time PCR and
array CGH.
Results: A hypermethylation of the SHOX2 locus in tumor tissue as compared to the matched NAT from the same
patient was detected in 96% of tumors from a group of 55 lung cancer patients. This correlated highly significantly
with the frequent occurrence of copy number amplification (p < 0.0001), while the expression of the SHOX2 gene
showed no difference.
Conclusions: Frequent gene amplification correlated with hypermethylation of the SHOX2 gene locus. This
concerted effect qualifies SHOX2 DNA methylation as a biomarker for lung cancer diagnosis, especially when
sensitive detection is needed, i.e. in bronchial lavage or blood samples.
Background
Lung cancer represents the second most common cancer
in both men and women and accounts for about 15% of
all cancer diagnoses [1]. In the absence of screening, lung
cancer patients either exhibit symptoms or are accidentally
diagnosed by clinical imaging performed for other indica-
tions. Patients suspected of having malignant lung disease
usually undergo clinical investigation (workup) including
CT-scanning of the thorax and bronchoscopy. The latter
is preferentially applied to confirm a lung neoplasm by
pathological assessment of tissue or a cytological specimen
obtained during the procedure. A final diagnosis after the
first bronchoscopy fails in about half of these patients [2],
which requires additional invasive diagnostic procedures.
Even when signs, symptoms and radiological findings are
such that the clinical diagnosis of malignant lung disease
appears obvious, it often takes considerable effort and
invasive procedures to obtain tissue material suitable for
definitively confirming the presence of malignant disease.
Ambiguous results following bronchoscopy are frequent
(i.e. the presence of a malignancy cannot be confirmed),
e.g. because the tumor is not visible endoscopically and
cells obtained by brushing or aspiration do not allow the
pathologist to confirm or exclude malignancy.
Biomarkers exhibit great potential for improving the
management of cancer in clinical routine. So far, several
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[3-5]. The use of DNA methylation as a biomarker is an
emerging field that provides potential for advancing the
clinical process of cancer diagnosis [6-10]. Methylation
of DNA is an important epigenetic process involved in
fundamental biological events such as development and
cell differentiation [for review: [11]]. Aberrant DNA
methylation has been reported to play a major role in
carcinogenesis [for review: [12]], suggesting that DNA
methylation analysis may be a valuable source for cancer
biomarkers [13]. Recently, SHOX2 DNA methylation
was shown to be a useful biomarker for detecting cancer
patients at high specificity and sensitivity in a group of
critical controls based on the analysis of bronchial
lavage samples [14]. Interestingly, samples that were
classified as ‘cytologically negative’ or ‘inconclusive’ due
to no (or too few) visible tumor cell content could be
identified as cancer-positive, based on their SHOX2
DNA methylation level.
SHOX2 has been identified as highly homologous to
the short stature homeobox gene SHOX. Both homeo-
domain-transcription factors are involved in skeletogen-
esis, and the murine Shox2 gene has been shown to play
a pivotal role during heart development [15-18].
Genomic gain of chromosome 3q involving the
SHOX2 gene has been recognized as one of the most
prevalent and significant chromosomal rearrangements
in lung cancer [19-23]. The positive performance of
SHOX2 DNA methylation as a biomarker in cytologi-
cally negative bronchial lavage samples might be due to
the concerted effects of locus amplification and DNA
methylation of SHOX2 in tumor cells. As a result, an
increase of SHOX2 DNA copies in tumor cells com-
pared to normal cells also increases the SHOX2 DNA
methylation level in a mixed sample of tumor and nor-
mal cells as compared to the methylation level of nor-
mal cells alone. In this study the DNA methylation,
gene expression and gene amplification of SHOX2 in
matched tumor and normal adjacent tissues (NAT)
from 55 lung cancer patients were investigated.
Methods
Patients
The study was comprised of matched morphologically
normal lung tissues and tumor tissues from 55 lung cancer
patients who underwent surgery. Surgical samples were
obtained from the ELK Berlin Chest Hospital (Berlin, Ger-
many). Histological data (histological subtype and grade)
can be found in Additional File 1. Appropriate consent in
line with institutional requirements was obtained from all
patients. The study protocol was approved by the local
ethics committees. All samples were fixed with RNAlater
and stored immediately at -80°C.
RNA Preparation
RNA was extracted using the RNeasy Mini Kit (Qiagen,
Hilden, Germany), following the manufacturer’s instruc-
tions. DNA contamination was eliminated by employing
the RNase-Free DNase Set (Qiagen, Hilden, Germany).
And RNA was reversely transcribed into cDNA using
the Superscript First Strand Synthesis System for RT-
PCR (Invitrogen, Carlsbad, CA). Nucleotide contents
were measured on a Nanodrop
® ND-1000 spectral
photometer (Nanodrop Technologies, DE, USA).
DNA Extraction
Washed research sperm (NW Andrology & Cryobank
Inc., Spokane, WA, USA) was lysed as previously
described [24]. Tumor tissues were lysed by adding 100
μl lysis buffer (50 mM Tris pH 8.4, 1 mM EDTA, 0.5%
[v/v] Tween
®20) and proteinase K (20 mg/ml, Carl
Roth, Karlsruhe, Germany) and incubated for 8 h at 60°
C and 1000 rpm in a thermomixer. Another 10 μlp r o -
teinase K was added and the samples were incubated for
another 4 h. Eighty μl of the lysate was subjected to the
bisulfite conversion reaction as described below. Geno-
mic DNA from the lysate was extracted as follows:
Twenty μl tumor tissue lysate was mixed with 180 μl
water, 250 μl binding buffer (6 M guanidiniumthiocya-
nate, 0.1 M Tris; pH 7.5) and 250 μl ethanol (molecular
biology grade, ≥ 99,8%). The mixture was transferred
onto a NucleoSpin Extract II Column (Macherey &
Nagel, Dueren, Germany) and was centrifuged at 14,000
× g for 3 min, and the flow-through was discarded. The
immobilized DNA was washed with 700 μlw a s hb u f f e r
(150 mM Tris pH 7.4, 85% ethanol) followed by three
rounds of centrifugation (14,000 × g, 1 min). The spin
column was incubated for 10 min at 60°C with open
lids in a thermomixer in order to evaporate residual
ethanol. Forty μl water was added to the centre of the
membrane and incubated for 1 min. The DNA was
eluted by centrifugation for 1 min at 14,000 × g.
DNA concentration was quantified using a Nanodrop
®
ND-1000 spectral photometer (Nanodrop Technologies,
DE, USA).
Bisulfite Conversion
Lysates from tumor tissues, universally methylated DNA
(CpGenome™ Universal Methylated DNA, Millipore,
MA, USA), and extracted DNA from sperm were filled
up with lysis buffer to a final volume of 80 μl and treated
as follows: Eighty μl bisulfite reagent (65% ABS, pH 5.3
[TIB Chemicals, Mannheim, Germany]) and 40 μl dena-
turation reagent (0.07 g/ml Trolox [Sigma-Aldrich, St.
Louis, MO] in THFA [VWR International, Darmstadt,
Germany]) were added and the mixture was incubated
for 45 min at 85°C and 1,000 rpm in a thermomixer.
Two hundred and fifty μl ethanol and 250 μlb i n d i n g
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extracted as described above with the following modifica-
tion: washing was carried out with 700 μl desulphonation
buffer (250 mM NaOH, 75% ethanol) after the first wash-
ing step.
DNA concentration was quantified via UV spectro-
photometry as described above.
Bisulfite converted sperm DNA (known to be
unmethylated at many loci [25]) and converted univer-
sally methylated DNA were mixed to produce samples
with a defined percentage of methylation.
SHOX2 DNA Methylation Real-time PCR Assays
Relative DNA methylation of the SHOX2 locus com-
pared to total DNA (determined via ACTB reference in
a duplex PCR reaction) was quantified using the Epi
proLung BL real-time PCR kit (Epigenomics AG, Berlin,
Germany) following the instructions for use, but only
0.25 μl DNA were subjected to PCR.
Relative DNA methylation of the SHOX2 locus
referred to total DNA as determined with a methyla-
tion-unspecific SHOX2 assay was analyzed in 20 μl
duplex PCR reaction with the following composition:
Thirty-five mM Tris, pH 8.4, 6 mM MgCl2,5 0m M
KCl, 5% glycerol, 0.25 mM each dNTP, 3 U FastStart
Taq DNA polymerase [GMP grade, Roche Diagnostics,
Mannheim, Germany], primers (0.3 μM5 ’-ggttttgagtaat-
taatagaaat-3’,0 . 3μM5 ’-ctctttctattctctcttc-3’,0 . 8μM5 ’-
gttttttggatagttaggtaat-3’,0 . 8μM5 ’-cctcctaccttctaaccc-3’),
1.5 μM each blocker (5’-taatttttgttttgtttgtttgattggg
gttgtatga-SpacerC3-3’,5 ’-acccaacttaaacaacaaacccttta-
SpacerC3-3’), 0.6 μM each detection probe (5’-6-R6G-
tgaatttgttgatttttgtgggt-BHQ1-3’,5 ’-6-FAM-ctcgtacgacccc-
gatcg-BBQ-650-3’)a n d2 0n gD N A( a c c o r d i n gt oU V
quantitation). The same PCR cycling was used as
described in the instructions for use of the Epi proLung
BL real-time PCR kit.
For each sample and each of the two assays as
described above, the relative methylation values were
determined using the ΔΔCT method [26,27]. Bisulfite
converted universally methylated DNA (as described
above) was used as reference DNA to transform ΔCT
into ΔΔCT. Therefore, a ΔΔCTSample = 0 refers to 100%
methylated DNA.
SHOX2 Copy Number Real-time PCR Assay
The methylation-unspecific quantification of the total
amount of bisulfite converted SHOX2 copies was per-
formed in 20 μl PCR reaction with the following compo-
sition: Tris, pH, MgCl2,K C l ,g l y c e r o l ,d N T P s ,F a s t S t a r t
Taq DNA polymerase as described above, 0.75 μMe a c h
primer (forward: 5’-ggttttgagtaattaatagaaat-3’, reverse: 5’-
ctctttctattctctcttc-3’), 0.3 μM detection probe (5’-6-
FAM-tgaatttgttgatttttgtgggt-BHQ1-3’)a n d2 0n gD N A
(according to UV quantitation). Ten ng of bisulfite con-
verted DNAs (0%, 25%, 50%, 75%, and 100% methylated)
were used as standards to convert the CT of a given
sample into ng of DNA. Each methylation mixture and
each sample were measured in triplicates and the mean
was calculated.
PCR was performed using a 7500 Fast Real-Time PCR
machine (Applied Biosystems, CA, USA) using the fol-
lowing temperature profile: 15 min at 95°C of initial
denaturation followed by 45 cycles with 15s, 95°C and
30s, 58°C.
SHOX2 qRT PCR Assay
qPCR was carried out in 20 μl reaction with the compo-
sition as described above but with the following
oligonucleotides:
SHOX2 variants a and b:f o r w a r d :5 ’-gtgttctca-
taggggccgccagc-3’, reverse: 5’-acagcgctgtccagctgcagctgcg,
probe: 5’-FAM-tcgcaccttatgtcaacgtaggtgc-BHQ1-3’
SHOX2a (NM_006884): forward primer and probe as
depicted for both variants, reverse: 5’-ggcgtcacgttgcaat-
gactat-3’
SHOX2b (NM_003030): forward primer and probe as
depicted for both variants, reverse: 5’-cagctgcgcct-
gaacctgc-3’
HPRT1 (NM_000194): forward: 5’-tgatagatccattcctat-
gactgtaga-3’, reverse: aagacattctttccagttaaagttgag-3’,
probe: 5’-FAM-cccctgttgactggtcattacaatagctc-BHQ1-3’
SDHA (NM_004168): forward: 5’-tgggaacaagaggg-
catctg-3’, reverse: 5’-ccaccactgcatcaaattcatg, probe: 5’-
FAM-ccatttctgctcagtatccagtagtgg-BHQ1-3’
PCRs were performed using a 7500 Fast Real-Time
PCR machine (Applied Biosystems, CA, USA) with the
following temperature profile: 30 min/25°C, 15 min/95°
C and 40 cycles with 15s/95°C and 1 min/60°C.
Array CGH
Whole-genome array comparative genomic hybridisation
(CGH) analysis was performed using a 1M oligonucleo-
tide array (Agilent, Santa Clara, CA) according to proto-
cols provided by the manufacturer. Image analysis,
normalization and annotation were based on Feature
Extraction 9.1 (Agilent, Santa Clara, CA) using the
default settings, and visualization of data was performed
with the DNA Analytics software (Agilent, Santa Clara,
CA). DNA from the matched NAT tissue was used as a
reference sample for the respective tumor DNA sample.
Statistical Analysis
The Kendall’s tau and Spearman rank correlation were
used to test whether DNA methylation and gene amplifi-
cation were statistically dependent. One-sided p-values
were reported. The Wilcoxon Rank-Sum was used to test
wether SHOX2 DNA methylation, gene amplification and
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subtypes.
Results
SHOX2 DNA methylation has previously been reported
to be applicable for the diagnosis of lung cancer based
on the analysis of bronchial lavage samples [14]. In this
study, the SHOX2 DNA methylation was quantified in
tumor tissues and morphologically normal adjacent tis-
sues from 55 lung cancer patients. In brief, this assay
represented a duplex real-time PCR consisting of a Hea-
vyMethyl (HM) assay [28] for sensitive and quantitative
detection of SHOX2 DNA methylation (promoter region
of transcript variant b [14]) and a reference PCR for
quantification of the total DNA using the ACTB locus.
A response curve of this assay is given in figure 1 with
different mixtures of bisulfite converted DNA from
sperm (known to be unmethylated at many loci [25])
and bisulfite converted DNA from artificially methylated
DNA. The assay allowed for highly accurate quantifica-
tion of the SHOX2 DNA methylation over a broad
range of relative methylation of the template DNA.
As indicated in figure 2, SHOX2 was methylated in the
vast majority of tumors. Ninety-six per cent (53 out of
55) of matched pairs showed a higher methylation level
in tumor tissues as compared to the matched NAT
from the same patient. The analyzed SHOX2 was signif-
icantly higher methylated in squamous cell carcinomas
as compared to adenocarcinomas (p = 0,0006 [Wilcoxon
Rank-Sum test], Additional File 1). Low SHOX2 DNA
methylation levels were also present in 55% (30 out of
55) of the NAT ranging from 0.01% to 0.3%. Interest-
ingly, the SHOX2 methylation level of three patients’
DNAs was above the theoretically expected maximum
of 100% (patient #1: 291%, patient #2: 130%, patient #3:
122%). This observation is unlikely to be a measurement
artefact since the response curve in figure 1 showed
high accuracy of the detection assay.
DNA methylation within the promoter region of a
gene is known to be part of a regulatory mechanism
that is able to silence gene expression [for review: [29]].
The correlation between SHOX2 DNA methylation and
gene expression was analyzed with three different quan-
titative real-time PCR assays. Two assays that were spe-
c i f i cf o rt h et r a n s c r i p tv a r i a n t sSHOX2aa n dSHOX2b,
respectively, which are suggested to be transcribed from
alternative promoters [15] were designed. The third
assay was designed to detect the total amount of
SHOX2 RNA transcripts. The relative expression level of
the two SHOX2a and b variants alone, as well as the
total amount of SHOX2 RNA in tumor tissues and nor-
mal tissues, is shown in figure 3 and Additional File 1.
A downregulation of SHOX2 expression due to a hyper-
methylation of the SHOX2 region in tumor tissues could
not be observed. Contrarily, the SHOX2 expression
seemed slightly elevated in tumor tissues, however, this
was not statistically significant.
G e n o m i cg a i no nc h r o m o s o m e3 q ,w h e r eSHOX2 is
located, has been recognized as one of the most preva-
lent and significant alterations in lung cancer [19-23].
Therefore, the SHOX2 copy numbers were analyzed in
order to investigate a potential correlation of SHOX2
DNA methylation and gene amplification. Quantities of
SHOX2 copy numbers were characterized by the ratio of
total SHOX2 DNA (to the total amount of DNA). The
amount of total DNA was quantified by UV spectropho-
tometry. Quantities of SHOX2 copies were measured
using a real-time PCR assay which specifically amplifies
bisulfite converted copies of the SHOX2 gene (methy-
lated and unmethylated). Even though the primers used
for this assay did not include CpG islands, a PCR bias (i.
e. preferred amplification of unmethylated or methylated
DNA), had to be excluded [30-32]. Otherwise, a more
efficient amplification of methylated DNA would result
in overestimated SHOX2 copy numbers in methylated
specimens. Therefore, mixtures (0 to 100%) of bisulfite
converted DNA from sperm and from artificially methy-
lated DNA were analyzed with respect to a potential
PCR bias. 20 ng DNA (according to UV) was subjected
to a triplicate real-time PCR analysis. The resulting CT
were 28.70 ± 0.33 (0% mixture), 28.55 ± 0.13 (25%),
28.54 ± 0.30 (50%), 28.37 ± 0.12 (75%), and 28.16 ± 0.11
(100%), respectively, indicating that no significant PCR
bias exists for this assay. The determined SHOX2 copy
numbers in relation to DNA methylation in the 55
tumor tissue samples is shown in figure 4 and Addi-
tional File 1. High SHOX2 DNA methylation was found
to correlate strongly with gene amplification (p = 0.0002
[Kendall’s tau rank correlation], p < 0.0001 [Spearman
rank correlation]). Amplification of the SHOX2 gene
locus did not differ significantly between adeno- and
squamous cell carcinomas.
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Figure 1 Response curve for the quantification of SHOX2 DNA
methylation. Mixtures of bisulfite converted DNA from sperm and
bisulfite converted artificially methylated DNA were used as
template DNA. Each methylation mixture (0, 0.8, 1.6, 3.1, 6.2, 12.5, 25,
50, and 100%) was measured in five replicates.
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Page 4 of 9DNA methylation of the SHOX2 locus as shown in
figure 4 was determined using a SHOX2/ACTB duplex
real-time PCR. The SHOX2 assay specifically amplified
methylated SHOX2 gene copies, while the ACTB pri-
mers amplified methylated and unmethylated copies of
the ACTB gene. Thus, it cannot be excluded that the
apparent higher relative SHOX2 methylation in tumors
with SHOX2 gene amplification is simply due to the
presence of higher numbers of total SHOX2 copies and
therefore also a higher number of methylated copies.
T h i sw o u l dr e s u l ti na no v e r e s t i m a t i o no ft h er e l a t i v e
methylation in samples with amplification of the SHOX2
locus. A sample where both SHOX2 gene copies are
methylated would result in a methylation level of 100%.
However, a methylation level of 200% would indicate
that the SHOX2 locus is duplicated when a different
locus, i.e. ACTB, is used for quantification of the total
DNA. Thus, the apparent relative methylation of the
SHOX2 locus correlates with the copy numbers due to
t h eu s a g eo fad i f f e r e n tl o c u sa sar e f e r e n c ea s s a y .T o
circumvent this overestimation of relative SHOX2
methylation a reference assay which is located at the
same locus was applied, where completely methylated
SHOX2 gene is determined as 100%, independent of
agene amplification. Thus, a duplex PCR was developed,
where methylated SHOX2 copies were directly corre-
lated to the total copy number of the SHOX2 gene itself.
The correlation of the SHOX2 methylation as deter-
mined with an ACTB and a SHOX2 assay for quantify-
ing total DNA is shown in figure 5 and Additional File
1. Using this duplex assay, none of the samples was
determined as methylated above 100%. This confirmed
that methylation determined by the ACTB reference
assay was overestimated for samples showing gene
amplification. However, the DNA methylation levels
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Figure 2 SHOX2 DNA methylation in tumor tissue and morphologically normal adjacent tissue (NAT) from 55 lung cancer patients.
Ninety-six percent (53/55) of patients exhibited a higher methylation value in tumor tissue as compared to the matched NAT. Fifty-five (30/55)
of the NAT showed a low SHOX2 methylation of 0.01 to 0.3%. SHOX2 DNA methylation levels in three tumors were significantly higher than
100%.
Figure 3 SHOX2 R N Ae x p r e s s i o ni nt u m o rt i s s u ea n d
morphologically normal adjacent tissue (NAT) from lung
cancer patients. Three qRT-PCR assays specific for both variants
and variant a (NM_006884) and b (NM_003030), respectively, were
used. Measurements were carried out in triplicates and normalized
to SDHA and HPRT1 genes. Valid results were obtained for NAT and
tumor tissues from 51 lung cancer patients.
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Figure 4 Correlation of gene amplification and DNA
methylation of the SHOX2 locus. SHOX2 copy numbers were
determined by relating the total amount of SHOX2 copies
(determined with real-time PCR) to the amount of total DNA as
quantified by UV. Methylation of the SHOX2 locus was measured
using a duplex PCR consisting of a HM assay for sensitive
quantification of methylated SHOX2 copies and an ACTB reference
assay. Means of a triplicate measurement are shown. Gene
amplification and DNA methylation correlate highly (p = 0.0002).
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Page 5 of 9quantified by both reference assays showed strong corre-
lation (p < 0.0001 [Kendall’s tau and Spearman rank
correlation]). In addition, DNA methylation quantified
with the SHOX2 reference assay still showed a signifi-
cant correlation with gene amplification (p = 0.002
[Kendall’s tau and Spearman rank correlation]).
Tumor tissue derived from patient #1 showed a very
high methylation rate of 291% (referred to ACTB)a n d
46% (referred to total SHOX2 copies), respectively, as
well as a strong copy number amplification of the
SHOX2 gene (4.9 fold). This tumor DNA was analyzed
in more detail using array CGH technology. A summary
of the CGH results are depicted in figure 6 showing that
the complete q arm of chromosome 3 is overrepresented
in the tumor. Taken together, this data clearly demon-
strate that the SHOX2 locus is highly amplified in the
tissue derived from patient #1. In summary, the pre-
sented results indicate that DNA methylation of the
SHOX2 gene highly correlates with the amplification of
its chromosomal location.
Discussion
SHOX2 DNA methylation, operating as a biomarker at a
high specificity and sensitivity in a group of lung cancer
patients and critical controls based on the analysis of
bronchial lavage samples, has recently been proven to
be a suitable means for diagnosing lung cancer [14].
The biomarker also worked with samples that contained
no visible tumor cell content. Since it has also been
found that genomic gain at chromosome 3q, including
SHOX2, is one of the most prevalent and significant
alterations in lung cancer [19-23], the objective of this
study was to investigate the relationship between gene
amplification, expression and DNA methylation of
SHOX2.I nt h i ss t u d y ,i tw a ss h o w nt h a ti n9 6 %o fa l l
cases of lung tumor patients, the SHOX2 gene is hyper-
methylated and frequently accompanied by increased
copy numbers of the respective locus. Hence, the posi-
tive performance of the SHOX2 DNA methylation as a
biomarker in cytologically negative bronchial lavage
samples might be due to a correlation of locus amplifi-
cation and DNA methylation in tumor cells. Genomic
amplification did not lead to a statistically significant
higher expression of SHOX2 a or b transcripts as com-
pared to the respective NAT. However, it has to be con-
sidered that SHOX2 mRNA levels were measured in
homogenized (lysed) tumor tissues. Therefore, the
extracted mRNA from tumor tissues is susceptible to
contamination by non-neoplastic cells. This contamina-
tion might mask tumor-specific alterations. Such con-
tamination affects mRNA expression analyses much
more dramatically as compared to DNA methylation
and gene amplification since the expected ranges (fold
changes) of mRNA expression between different cell
types can be much higher. In cancer research, the devel-
opment of laser microdissection (LMD) systems has
addressed this dilemma and could be implemented in
the future to study SHOX2 expression in distinct tumor
cell types.
Interestingly, NAT also showed low levels of methyla-
tion (< 0.3%). This observation might arise from a
potential field effect, leading to alterations of methyla-
tion in normal components adjacent to the tumor, or
from the existence of a subpopulation of cells with simi-
larities to the tumor cells on an epigenetic level. Altera-
tions of methylation in NAT and the existence of a
subpopulation of cells within the normal epithelia with
epigenetic similarities to the tumor cells have previously
been reported in several cancers [33,34]. In addition,
tumor development and progression occur as an inter-
action between tumor cells and their stromal environ-
ment [for review: [35,36]], and the concept of epithelial
to mesenchymal transition (EMT) as a driver of tumor
progression has become more important in recent years
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Figure 5 Correlation of SHOX2 methylation in 55 tumors as determined using ACTB and SHOX2 as references. Left: Scatter plot of SHOX2
methylation. SHOX2 methylation was determined with an ACTB reference assay (x-axis) and a methylation unspecific SHOX2 reference assay (y-
axis), respectively, for quantification of total DNA in a duplex PCR. Means of a triplicate measurement are shown. Right: Scatter plot of ranks. The
methylation values as determined with both reference assays were ranked and the respective ranks were correlated.
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Page 6 of 9[37,38]. Thus, cells, which might not allow for a mor-
phological cancer diagnosis do already harbour the can-
cerogenic information by their epigenetic state.
However, in order to address the question of whether
methylation in NAT comes from such a field effect or is
also present in tissue from healthy individuals, normal
components at larger distances from the tumor or in tis-
sue from healthy controls would have to be analyzed.
Both, a potential field effect on an epigenetic level, as
well as a concerted mechanism of gene amplification
and DNA methylation, renders DNA methylation an
attractive source of biomarkers for the diagnosis of can-
cer in body fluids where sensitive detection is required.
The reinforced epigenetic signal, together with chromo-
somal rearrangements and thus locus amplifications,
may be part of a cellular mechanism during tumorigen-
esis. Therefore, DNA methylation may be preferrentially
employed as a diagnostic test compared to methods
based on cell counting. Additionally, the detection and
accurate quantification of DNA is easier as compared to
protein and RNA, due to the higher stability of DNA in
quantitative real-time PCR. This study also indicates
that a combination of genome-wide DNA methylation
analysis, i.e. MeDIP and DMH, and CGH is effective for
the screening of candidate marker genes and therefore
might also influence the discovery of novel biomarkers
for clinical applications. A multiplexing of such markers,
ideally from different chromosomes might further
improve a diagnostic test.
However, the functional relationship between DNA
methylation and amplification as well as the underlying
pathomechanism remains to be elucidated. It is not yet
clear whether DNA methylation is a response reaction
to locus amplification or if DNA hypermethylation pro-
motes destabilization of the genome and with that gene
amplification. However, it is well acknowledged that a
genome-wide hypomethylation induces chromosomal
instability [for review: [11]] and that genome-wide hypo-
methylation in cancer goes hand-in-hand with gene-spe-
cific hypermethylation, e.g. of tumor suppressor genes
[for review: [39]]. Thus, SHOX2 hypermethylation in
lung cancer might be indicative of an overall hypo-
methylation of the corresponding chromosomal region
and therefore of genetic instability which results in gene
amplification.
Conclusions
The tumor-specific hypermethylation of SHOX2 and its
frequent gene amplification in lung cancer renders
SHOX2 DNA methylation is an attractive biomarker for
lung cancer when sensitive detection is desired, i.e. in
bronchial lavage specimens.
Additional material
Additional file 1: Patient information and SHOX2 data. This excel
spreadsheet (.xls) contains the histological subtypes and the measured
SHOX2 methylation, gene amplification and expression data for each
patient.
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